BURNABY, BC, April 20 /CNW/ - Welichem Biotech Inc. announces the start of GLP toxicology studies for its lead, anti-inflammatory drug WBI-1001. The long-term toxicology studies that are currently underway are designed to support the filing of an Investigational New Drug (IND) application for WBI-1001 with the U.S. FDA so as to initiate Phase II/III clinical studies in the US. Welichem intends to submit an IND for WBI-1001 in the Fall of 2009, following successful completion of the toxicology program.
